Orphan drugs and the NHS: should we value rarity?
McCabe
Christopher
C
White Rose Initiative in Health Technology Assessment, Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield S1 4DA. c.mccabe@sheffield.ac.uk
Claxton
Karl
K
Tsuchiya
Aki
A
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006304:Health Status; D006801:Humans; D009965:Orphan Drug Production / Q000191:economics; D035583:Rare Diseases / Q000188:drug therapy*; D013222:State Medicine / Q000191:economics; D016896:Treatment Outcome